Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | GCG | P01275 | 4/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240030 | 0.83 | LTC4S (0.42) | GCGP4HTMLTC4S | |
| SCHEMBL229858 | 0.78 | MAPT (0.47) | P4HTMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL234583 | 0.76 | LTC4S (0.60) | LTC4S | |
| SCHEMBL234584 | 0.75 | ATM (0.39) | P4HTMLTC4SMAPK1MAPTATM | |
| SCHEMBL27832535 | 0.73 | LTC4S (0.41) | LTC4S | |
| SCHEMBL9988057 | 0.71 | LTC4S (0.50) | LTC4S | |
| SCHEMBL9988113 | 0.71 | LTC4S (0.44) | P4HTMLTC4SPOLB | |
| SCHEMBL1721644 | 0.70 | MDM2 (0.42) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16752637 | 0.70 | SMN1; SMN2 (0.47) | MAPTMEN1KMT2ANPC1 | |
| SCHEMBL9988164 | 0.70 | LTC4S (0.45) | P4HTMLTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406220-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| WO-2010103279-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | PLA2G1B 341/4885ATG4B 2960/4885GCG 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.